
ZEISS concludes fiscal year 2024/25 with solid growth
Oberkochen, Germany - Revenue totaled almost 12 billion euros, with EBIT at 1.552 billion euros. The segments once again presented a mixed picture. Targeted resilience measures and investments in innovative strength are the key to the future.

- Mixed picture in all four segments
- Targeted resilience measures continued
- Expenditure resilience measures continued
- Current outlook challenging
The ZEISS Group concluded fiscal year 2024/25 with solid growth. Revenue increased to 11.896 billion euros (prior year: 10.894 billion euros, up 9%), and earnings before interest and taxes (EBIT) reached 1.552 billion euros (prior year: 1.444 billion euros), giving an EBIT margin of 13%. The result, particularly the mixed picture in the four segments, reflects the increasing geoeconomic and geopolitical challenges that the company faced in the past fiscal year.
"ZEISS is still operating in a dynamic and challenging business environment," said Andreas Pecher, President and CEO of the ZEISS Group. Geopolitical tensions, trade barriers, and the conflicts between the major economic regions intensified further in fiscal year 2024/25. This directly impacted the willingness of industry to invest, as well as consumer confidence. "There was increased uncertainty in the markets in the past fiscal year. This required us to adapt strategic activities and strengthen targeted resilience measures," Pecher explained.
|
Segment development |
|||
|
Revenue (in billion euros) |
|||
|
Fiscal year 2024/25 |
Fiscal year 2023/24 |
Change (adjusted for currency effects) |
|
|
Semiconductor Manufacturing Technology |
5.055 |
4.122 |
+23% (+23%) |
|
Industrial Quality & Research |
2.334 |
2.369 |
-1% (0%) |
|
Medical Technology1 |
2.704 |
2.611 |
+4% (+6%) |
|
Consumer Markets |
1.569 |
1.541 |
+2% (+4%) |
1Not identical to the Carl Zeiss Meditec Group
The full press release can be found at www.zeiss.com/newsroom
Keywords
Contacts
Jörg NitschkeHead of Corporate Brand, Communications and Public AffairsZEISS Group
Tel:+49 7364 20-3242joerg.nitschke@zeiss.comwww.zeiss.comImages

Subscribe to releases from Carl Zeiss AG
Subscribe to all the latest releases from Carl Zeiss AG by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Carl Zeiss AG
Good overall result and revenue growth for the ZEISS Group17.12.2024 10:45:00 CET | Press release
Oberkochen - ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide.
ZEISS Celebrates 175 Years of Innovation, Passion and the Courage to Develop17.11.2021 10:00:00 CET | Press release
175 years ago, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become ZEISS.
Half-Year Figures: ZEISS Reports Successful Start to Fiscal Year19.5.2021 11:15:00 CEST | Pressemeddelelse
Half-year revenue reaches 3.4 billion euros (+6% compared to prior year) – EBIT at 591 million euros (+136 million euros vs. prior year) Positive development across all ZEISS segments ZEISS Group successfully navigates pandemic thanks to broad portfolio and global structure In particular, Medical Technology and Consumer Markets segments currently the biggest contributors to growth High investments in Research & Development continue as 12% of revenue dedicated to this area OBERKOCHEN, GERMANY, 19 May 2021 The ZEISS Group had a successful end to the first six months of fiscal year 2020/21 (ended 31 March 2021). It saw its revenue rise by 6 percent (adjusted for currency fluctuations, by 9 percent) to 3.406 billion euros (previous year: 3.213 billion euros). Around 90% of this sum was generated in markets outside Germany. At 591 million euros, earnings before interest and tax (EBIT) were significantly higher than in the previous year (455 million euros). The EBIT margin was 17%. Incoming
Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed27.8.2020 10:41:00 CEST | Press release
New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published*